Healthcare Mar 10, 2022 02:16 PM (GMT+8) · EqualOcean
On the evening of March 9, poten announced that in order to match the rapid growth of preclinical and early clinical (CRO) business development needs, Chongqing poten Pharmaceutical Technology Co., Ltd. plans to acquire 100% equity of Kaihui Pharmaceutical (Shanghai) Co., Ltd. held by Shanghai Ruizhi Chemical Research Co., Ltd. at a price of RMB 266 million. After the completion of this transaction, the company will hold 100% equity of Kaihui pharmaceutical, which will become a wholly-owned subsidiary of the company and be included in the scope of the company's consolidated financial statements.